An analyst report published August 19, 2026, issued a Strong Sell rating for Clover Health Investments. The analysis set a $2.40 price target, claiming current valuations overstate potential profitability.
Structural low-margin realities and regulatory constraints currently limit cash flow. Statutory capital reserve requirements also restrict the company's ability to issue dividends.
High medical loss ratios and uncertainty regarding CMS bonus payments from a 4.5-star rating present ongoing risks. These fundamental challenges persist despite recent membership growth and AI-driven cost management.